Table 3 Clinical outcomes at 12-month follow-up stratified according to diabetic status and type of lesion (de-novo lesions vs. ISR)
|  | Overall population (N = 2,083) | Patents with de-novo lesions (N = 1,173) | Patients with ISR (N = 910) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Patients with DM (N = 864) | Patients without DM (N = 1,219) | HR (95% CI) | Patients with DM (N = 452) | Patients without DM (N = 721) | HR (95% CI) | Patients with DM (N = 412) | Patients without DM (N = 498) | HR (95% CI) |
Death, n (%) | 33 (3.8) | 32 (2.6) | 1.81 (0.95–3.46) | 10 (2.2) | 14 (1.9) | 1.80 (0.58–5.64) | 23 (5.6) | 18 (3.6) | 1.74 (0.79–3.81) |
MI, n (%) | 29 (3.4) | 18 (1.5) | 2.15 (1.09–4.25) | 8 (1.8) | 3 (0.4) | 2.44 (0.57–10.46) | 21 (5.1) | 15 (3.0) | 1.90 (0.88–4.09) |
Bleeding, n (%) | 9 (1.0) | 4 (0.3) | 2.65 (0.75–9.31) | 3 (0.7) | 3 (0.4) | 1.49 (0.29–7.60) | 6 (1.5) | 1 (0.2) | 7.26 (0.71–74.20) |
MACE, n (%) | 105 (12.2) | 109 (8.9) | 1.26 (0.92–1.74) | 27 (6.0) | 40 (5.5) | 1.05 (0.59–1.85) | 78 (18.9) | 69 (13.9) | 1.39 (0.94–2.04) |
TLR, n (%), per-patient | 52 (6.0) | 61 (5.0) | 1.15 (0.73–1.81) | 9 (2.0) | 13 (1.8) | 1.00 (0.39–2.59) | 43 (10.4) | 48 (9.6) | 1.13 (0.67–1.90) |
TLR, n/lesion number (%), per lesion | 63/968 (6.5) | 64/1371 (4.7) | 1.38 (0.91–2.08) | 11/486 (2.3) | 13/798 (1.6) | 1.35 (0.56–3.26) | 52/482 (10.8) | 51/573 (8.9) | 1.36 (0.85–2.16) |